Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

Annals of surgery·2026
Same author

Global Consensus on the Management of Primary Localized Chordoma.

JAMA oncology·2026
Same author

Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.

European radiology experimental·2026
Same author

Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

ASO Visual Abstract: Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis using Radiomics: An International Multi-center Cohort Study.

Annals of surgical oncology·2026

Related Experiment Video

Updated: May 2, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective,

Dario Callegaro1, Gabriele Tinè2, Sandro Pasquali3

  • 1Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

The Lancet. Oncology
|April 30, 2026
PubMed
Summary

BayeSarc, a new prognostic model using Bayesian sequential learning, offers more accurate survival and metastasis predictions for soft tissue sarcomas than Sarculator. This continuously updatable tool improves patient care and clinical trial design.

More Related Videos

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.0K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.3K

Related Experiment Videos

Last Updated: May 2, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.0K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.3K

Area of Science:

  • Oncology
  • Biostatistics
  • Medical Informatics

Background:

  • Sarculator is a validated prognostic tool for soft tissue sarcomas but lacks adaptability.
  • External validation was used, limiting its ability to incorporate new data or adapt to temporal changes.

Purpose of the Study:

  • To develop BayeSarc, a prognostic model using Bayesian sequential learning (BSL).
  • To enable continuous updating of prognostic estimates by incorporating new clinical cohorts.
  • To provide more accurate survival and metastasis predictions compared to Sarculator.

Main Methods:

  • Retrospective, multicentre cohort study of 4916 adult patients with resected soft tissue sarcomas.
  • BayeSarc was developed using a historical cohort and sequentially updated with five independent cohorts.
  • Bayesian Cox and Fine-Gray models were used within a BSL framework for updating and adaptive borrowing.

Main Results:

  • BayeSarc demonstrated superior discrimination for overall survival (C index 0.801) and distant metastasis (C index 0.738) compared to Sarculator (0.773 and 0.718, respectively).
  • Calibration consistently improved across updates, and predictive uncertainty decreased.
  • The model was evaluated using prequential and post-update estimates.

Conclusions:

  • BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas.
  • The BSL framework offers an innovative and generalizable approach for prognostication in rare cancers.
  • Integration into the Sarculator app allows immediate clinical use, potentially improving patient counseling, treatment decisions, and trial design.